Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

68.20 +0.02 (+0.03%)
Official Closing Price Updated: 7:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
5 Stocks That Michael Burry Just Dumped From His Portfolio
Now holding just one stock in his portfolio, contrarian investor Michael Burry has cashed out of these five stocks. 
Via InvestorPlace
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
S&P 500 Stock Market Winners Today
Diamondback Energy was the index's top performer Monday. 
Via Investor's Business Daily
Why Bristol-Myers Squibb Stock Fell Today
Bristol-Myers Squibb Co (NYSE: BMY) shares traded lower Monday after the company announced, in collaboration with Janssen Pharmaceuticals, that the results from the Phase 2 AXIOMATIC-SSP dose-ranging... 
Via Benzinga
Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review
 
Via Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 14.5% since its last report. The company recently reported that it has 23.84 million shares sold short,... 
Via Benzinga
Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops
The companies hoped to reduce the risk of myriad complications for at-risk patients. 
Via Investor's Business Daily
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials
 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Bristol Myers Squibb Secures Canadian Regulatory Nod For Lung Cancer Candidate In Neoadjuvant Setting
Health Canada announced approval for Bristol Myers Squibb’s (NASDAQ: BMY) OPDIVO (nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks... 
Via Benzinga
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie. 
Via Investor's Business Daily
What Are Whales Doing With Bristol-Myers Squibb
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Michael Burry Puts His Money Where His Mouth Is For Market Crash Prediction: But Did He Sell Too Soon?
Famed “Big Short” investor Michael Burry has taken an extremely bearish stance during the third quarter of 2022 — but was it too much? 
Via Benzinga
NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition
NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for  
Via Benzinga
Blue Chip Stocks In Focus: Bristol-Myers Squibb
The company has grown earnings by more than 20% per year on average over the last five and ten years. This explosive growth has enabled the company to continue growing its dividend. 
Via Talk Markets
Why Michael Burry Is Betting Big on Just ONE Secretive Stock
Shares of GEO stock are in full focus after Michael Burry's Scion Asset Management reported the prison company as its only 13F holding. 
Via InvestorPlace
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
 
Via Benzinga
TC BioPharm Says It Aims To Deliver A Big Breakthrough In Cancer Treatments
Approximately 1.7 million new cancer cases are reported every year in the United States. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Looking At Bristol-Myers Squibb's Recent Whale Trades
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Analyzing Bristol-Myers Squibb's Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 29.89% since its last report. The company recently reported that it has 27.33 million shares sold short,... 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
The major indexes made big moves amid key earnings and another big Fed rate hike. 
Via Investor's Business Daily
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty. 
Via Benzinga
Bristol Myers Squibb Q2 Earnings And Revenues Surpass Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.93 per share. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.